相关实验视频
Updated: Jul 22, 2026

Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
道路交通事故与使用二二类药物的关联
F Barbone1, A D McMahon, P G Davey
1Department of Clinical Pharmacology and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, UK.
使用焦虑缓解剂二和佐皮克隆的司机面临更高的道路交通事故风险. 这些发现表明,服用这些药物的个人应该建议不要开车,以提高道路安全.
科学领域:
- 药理学 药理学是指药理学的学科.
- 交通安全 交通安全
- 流行病学 流行病学
背景情况:
- 精神运动研究表明,精神活性药物可以损害驾驶能力.
- 这项研究调查了精神药物使用和道路交通事故之间的联系.
研究的目的:
- 检查特定精神药物使用与道路交通事故风险之间的关联.
- 为了比较暴露和未暴露于精神活性药物的司机之间的事故风险.
主要方法:
- 一个案例交叉研究设计被采用使用分发的处方数据.
- 该研究包括18岁以上的英国泰赛德的司机,他们在1992年8月至1995年6月期间首次发生道路交通事故.
- 暴露被定义为在事故发生之前使用三环抗抑郁药,二,选择性血清素再吸收抑制剂或其他精神活性药物.
主要成果:
- bensodiazepine 使用与道路交通事故的风险显著增加有关 (OR 1.62,95% CI 1.24-2.12).
- bensodiazepine 用户的风险随着年龄的增长而降低,并且因阳性酒精呼吸测试而放大.
- 观察到与二类药物,特别是半衰期较长的抗焦虑药和半衰期较短的催眠药 (如佐皮克隆) 的剂量反应关系.
结论:
- 焦虑缓解剂二和佐皮克隆的使用者有较高的道路交通事故风险.
- 医疗保健专业人员应建议使用焦虑缓解剂二和佐皮克隆的患者不要开车.
更多相关视频
07:54Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test
Published on: June 29, 2018
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
相关概念视频
CNS Depressants: Barbiturates and Benzodiazepines
Anxiolytic Drugs: Benzodiazepines and Buspirone
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...